Provided by Tiger Trade Technology Pte. Ltd.

Arcus Biosciences Inc.

30.34
+0.82002.78%
Volume:1.06M
Turnover:31.97M
Market Cap:3.86B
PE:-7.85
High:30.56
Open:29.89
Low:29.74
Close:29.52
52wk High:31.74
52wk Low:10.07
Shares:127.33M
Float Shares:89.84M
Volume Ratio:0.70
T/O Rate:1.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8641
EPS(LYR):-3.2900
ROE:-90.82%
ROA:-30.39%
PB:8.33
PE(LYR):-9.22

Loading ...

Arcus Biosciences Announces Clinical Supply Agreement with Aveo Oncology

Reuters
·
Jul 23

Arcus Biosciences, Summit Therapeutics Team up to Test Casdatifan-ivonescimab Combo in Kidney Cancer

Reuters
·
Jul 23

Arcus Biosciences - Aveo to Supply Tivozanib; Arcus to Sponsor Study; Each Retains Rights to Compounds

THOMSON REUTERS
·
Jul 23

Arcus Biosciences - Enrollment for New Arc-20 Cohort Expected to Begin in Q4 2026

THOMSON REUTERS
·
Jul 23

Arcus Biosciences Inc: Initial Data from This Clinical Trial Collaboration is Expected to be Generated by Mid-2027

THOMSON REUTERS
·
Jul 23

Arcus Biosciences Inc: Both Cos Will Contribute to Cost of Study, Each Co Will Retain Development & Commercial Rights to Their Respective Molecules

THOMSON REUTERS
·
Jul 23

Arcus Biosciences Inc: Under Terms of Agreement, Summit Will Supply Ivonescimab and Arcus Will Conduct and Sponsor Combination Study

THOMSON REUTERS
·
Jul 23

Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer

THOMSON REUTERS
·
Jul 23

Press Release: Arcus Biosciences to Host Conference Call to Discuss Second-quarter 2026 Financial Results and Pipeline Updates

Dow Jones
·
Jul 22

Arcus Biosciences Schedules Call on Second-quarter Financial Results and Pipeline Update

Reuters
·
Jul 22

Arcus Biosciences is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jul 20

Arcus Biosciences price target raised to $45 from $32 at H.C. Wainwright

TIPRANKS
·
Jul 20

Arcus Biosciences President Juan C. Jaen Disposes of $2.05 Million in Common Shares

Reuters
·
Jul 14

Arcus Biosciences Grants Inducement Stock Options for 16,060 Shares at $30.26 Each

Reuters
·
Jul 10

Arcus Biosciences announces publication on ARC-20 study research

TIPRANKS
·
Jul 01

Arcus Biosciences Opens New Front With First-In-Human Trial of AB102

TIPRANKS
·
Jun 26

Arcus Bio President Juan C. Jaen Disposes of USD 852,805 in Common Shares

Reuters
·
Jun 25

Arcus Biosciences Grants New Hires Options for 18,400 Shares at $28.18 Each

Reuters
·
Jun 25

Arcus Biosciences shareholders re-elect Class II directors at annual meeting

Reuters
·
Jun 13

Is Arcus Biosciences (RCUS) Using the ROSETTA Trial Tie-Up to Quietly Reframe Its RCC Strategy?

Simply Wall St.
·
Jun 12